Alteraciones hematológicas como consecuencia de COVID-19 y sus vacunas

Palabras clave: COVID-19, SARS-CoV-2, hematología, pronóstico, parámetros, marcadores, coagulación, coagulopatía, trombosis, plaquetas, vacunas.

Resumen

El virus SARS-CoV-2 continúa infectando a millones de individuos en el mundo. Aunque los síntomas más frecuentes observados en los pacientes con COVID-19 son fiebre, fatiga y tos, en los casos severos la hipercoagulabilidad y la inflamación son dos condiciones que pueden producir complicaciones y causar daño en órganos, poniendo en riesgo la vida del paciente. Con el fin de clasificar a los pacientes durante el triaje, se han explorado diferentes marcadores hematológicos, incluidos el recuento de plaquetas, linfocitos y eosinófilos, y la relación neutrófilos/linfocitos, entre otros. Por su parte, para la evaluación de las coagulopatías, se vienen determinando marcadores como el dímero D y el fibrinógeno. En esta revisión se abordan las coagulopatías y los parámetros hematológicos en pacientes con COVID-19, al igual que las anormalidades en la coagulación como la trombocitopenia trombótica inmune inducida por las vacunas contra el SARS-CoV-2.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Jennifer C. Vizcaíno-Carruyo, Editora Médica Colombiana S.A.

Médica, Especialista en Hematología. Asistente Científica, Editora Médica Colombiana S.A. Medellín, Colombia.

Ana Isabel Toro-Montoya, Editora Médica Colombiana S.A.

Bacterióloga y Laboratorista Clínica, MSc en Virología. Directora Científica, Editora Médica Colombiana S.A. Medellín, Colombia.

Referencias bibliográficas

Mendiola-Pastrana IR, López-Ortiz E, Río de la Loza-Zamora JG, González J, Gómez-García A, López-Ortiz G. SARS-CoV-2 variants and clinical outcomes: A systematic review. Life 2022;12:170. https://doi.org/10.3390/life12020170.

Tiecco G, Storti S, Degli Antoni M, Focà E, Castelli F, Quiros-Roldan E. Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: A literature review. Int J Mol Sci 2022;23. https://doi.org/10.3390/ijms23041987.

Bahraini M, Dorgalaleh A. The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19. Semin Thromb Hemost 2022;48:19-30. https://doi.org/10.1055/s-0041-1736166.

Blomme S, Smets L, Van Ranst M, Boeckx N, Van Laer C. The influence of COVID-19 on routine hematological parameters of hospitalized patients. Acta Clin Belg 2022;77:241-246. https://doi.org/10.1080/17843286.2020.1814649.

Dubey DB, Mishra S, Reddy HD, Rizvi A, Ali W. Hematological and serum biochemistry parameters as a prognostic indicator of severally ill versus mild Covid-19 patients: A study from tertiary hospital in North India. Clin Epidemiol Glob Health 2021;12:100806. https://doi.org/10.1016/j.cegh.2021.100806.

Yang H, Xu Y, Li Z, Yan L, Wang J, Liao P. The clinical implication of dynamic hematological parameters in COVID-19: A retrospective study in Chongqing, China. Int J Gen Med 2021;14:4073-4080. https://doi.org/10.2147/ijgm.S321292.

Ghazanfari T, Salehi MR, Namaki S, Arabkheradmand J, Rostamian A, Rajabnia Chenary M, et al. Interpretation of hematological, biochemical, and immunological findings of COVID-19 disease: Biomarkers associated with severity and mortality. Iran J Allergy Asthma Immunol 2021;20:46-66. https://doi.org/10.18502/ijaai.v20i1.5412.

Elkhalifa AME, Elderdery AY, Al Bataj IA, Tamomh AG, Alyami MM, Almakrami HA, et al. Hematological findings among COVID-19 patients attending King Khalid Hospital at Najran, Kingdom of Saudi Arabia. Biomed Res Int 2022;2022:4620037. https://doi.org/10.1155/2022/4620037.

Al-Saadi E, Abdulnabi MA. Hematological changes associated with COVID-19 infection. J Clin Lab Anal 2022;36:e24064. https://doi.org/10.1002/jcla.24064.

Suryawanshi SY, Priya S, Sinha SS, Soni S, Haidry N, Verma S, et al. Dynamic profile and clinical implications of hematological and immunological parameters in COVID-19 patients. A retrospective study. J Family Med Prim Care 2021;10:2518-2523. https://doi.org/10.4103/jfmpc.jfmpc_2400_20.

Taj S, Kashif A, Arzinda Fatima S, Imran S, Lone A, Ahmed Q. Role of hematological parameters in the stratification of COVID-19 disease severity. Ann Med Surg (Lond) 2021;62:68-72. https://doi.org/10.1016/j.amsu.2020.12.035.

Saurabh A, Dey B, Raphael V, Barman B, Dev P, Tiewsoh I, et al. Evaluation of hematological parameters in predicting intensive care unit admission in COVID-19 patients. SN Compr Clin Med 2022;4:39. https://doi.org/10.1007/s42399-021-01115-8.

Damiati LA, Bahlas S, Aljohaney A, Bawazir Y, Mustafa M, Denetiu I, et al. Implications of SARS-CoV-2 infection on the clinical, hematological, and inflammatory parameters in COVID-19 patients: A retrospective cross-sectional study. J Infect Public Health 2022;15:214-221. https://doi.org/10.1016/j.jiph.2021.12.013.

Szklanna PB, Altaie H, Comer SP, Cullivan S, Kelliher S, Weiss L, et al. Routine hematological parameters may be predictors of COVID-19 severity. Front Med (Lausanne) 2021;8:682843. https://doi.org/10.3389/fmed.2021.682843.

Alkan G, Sert A, Emiroglu M, Tuter Oz SK, Vatansev H. Evaluation of hematological parameters and inflammatory markers in children with COVID-19. Ir J Med Sci 2021:1-9. https://doi.org/10.1007/s11845-021-02762-5.

Ötiken-Arıkan K, Şahinkaya Ş, Böncüoğlu E, Kıymet E, Cem E, Akaslan-Kara A, et al. Can hematological findings of COVID-19 in pediatric patients guide physicians regarding clinical severity? Turk J Haematol 2021;38:243-245. https://doi.org/10.4274/tjh.galenos.2021.2021.0157.

Shokri P, Golmohammadi S, Noori M, Nejadghaderi SA, Carson-Chahhoud K, Safiri S. The relationship between blood groups and risk of infection with SARS-CoV-2 or development of severe outcomes: A review. Rev Med Virol 2022;32:e2247. https://doi.org/10.1002/rmv.2247.

Saleh M, Alkofide A, Alshammari A, Siddiqui K, Owaidah T. Changes in hematological, clinical and laboratory parameters for children with covid-19: Single-center experience. J Blood Med 2021;12:819-826. https://doi.org/10.2147/jbm.S321372.

Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021;21:319-329. https://doi.org/10.1038/s41577-021-00536-9.

Abrignani MG, Murrone A, De Luca L, Roncon L, Di Lenarda A, Valente S, et al. COVID-19, vaccines, and thrombotic events: A narrative review. J Clin Med 2022;11. https://doi.org/10.3390/jcm11040948.

Chen AT, Wang CY, Zhu WL, Chen W. Coagulation disorders and thrombosis in COVID-19 patients and a possible mechanism involving endothelial cells: A review. Aging Dis 2022;13:144-156. https://doi.org/10.14336/ad.2021.0704.

Sbirkov Y, Dzharov V, Todorova K, Hayrabedyan S, Sarafian V. Endothelial inflammation and dysfunction in COVID-19. Vasa 2022;51:62-70. https://doi.org/10.1024/0301-1526/a000991.

Cryer MJ, Farhan S, Kaufmann CC, Jäger B, Garg A, Krishnan P, et al. Prothrombotic milieu, thrombotic events and prophylactic anticoagulation in hospitalized COVID-19 positive patients: A review. Clin Appl Thromb Hemost 2022;28:10760296221074353. https://doi.org/10.1177/10760296221074353.

Sastry S, Cuomo F, Muthusamy J. COVID-19 and thrombosis: The role of hemodynamics. Thromb Res 2022;212:51-57. https://doi.org/10.1016/j.thromres.2022.02.016.

Iba T, Warkentin TE, Thachil J, Levi M, Levy JH. Proposal of the definition for COVID-19-associated coagulopathy. J Clin Med 2021;10:191. https://doi.org/10.3390/jcm10020191.

Teimury A, Khameneh MT, Khaledi EM. Major coagulation disorders and parameters in COVID-19 patients. Eur J Med Res 2022;27:25. https://doi.org/10.1186/s40001-022-00655-6.

Ulanowska M, Olas B. Modulation of hemostasis in COVID-19; blood platelets may be important pieces in the COVID-19 puzzle. Pathogens (Basel, Switzerland) 2021;10:370. https://doi.org/10.3390/pathogens10030370.

Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and antithrombotic treatment in coronavirus 2019: A new challenge. Thromb Haemost 2020;120:949-956. https://doi.org/10.1055/s-0040-1710317.

Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-1720. https://doi.org/10.1056/NEJMoa2002032.

La Torre G, Marte M, Massetti AP, Carli SM, Romano F, Mastroianni CM, et al. The neutrophil/lymphocyte ratio as a prognostic factor in COVID-19 patients: a case-control study. Eur Rev Med Pharmacol Sci 2022;26:1056-1064. https://doi.org/10.26355/eurrev_202202_28017.

Castillo-Martínez D, Torres Z, Amezcua-Guerra LM, Pineda C. Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19? Clin Rheumatol 2021;40:3015-3019. https://doi.org/10.1007/s10067-021-05724-5.

Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: Time for a reality check? Semin Thromb Hemost 2022;48:72-92. https://doi.org/10.1055/s-0041-1728832.

Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W, et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol 2020;72:1998-2004. https://doi.org/10.1002/art.41425.

Al-Ali D, Elshafeey A, Mushannen M, Kawas H, Shafiq A, Mhaimeed N, et al. Cardiovascular and haematological events post COVID-19 vaccination: A systematic review. J Cell Mol Med 2022;26:636-653. https://doi.org/10.1111/jcmm.17137.

Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol 2022;9:e73-e80. https://doi.org/10.1016/s2352-3026(21)00306-9.

Mohseni-Afshar Z, Babazadeh A, Janbakhsh A, Afsharian M, Saleki K, Barary M, et al. Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: A clinical dilemma for clinicians and patients. Rev Med Virol 2022;32:e2273. https://doi.org/10.1002/rmv.2273.

Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med 2022. https://doi.org/10.1016/j.tcm.2022.02.008.

Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood 2021;138:293-298. https://doi.org/10.1182/blood.2021012152.

Bussel JB, Connors JM, Cines DB, Dunbar CE, Michaelis LC, Baumann-Kreuziger L, et al. Vaccine-induced Immune thrombotic thrombocytopenia. Washington: American Society of Hematology; 2022. Acceso 30 de marzo de 2022. Disponible en https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia.

Ahmed SH, Shaikh TG, Waseem S, Qadir NA, Yousaf Z, Ullah I. Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: A narrative review. Ann Med Surg (Lond) 2022;73:102988. https://doi.org/10.1016/j.amsu.2021.102988.

Bilotta C, Perrone G, Adelfio V, Spatola GF, Uzzo ML, Argo A, et al. COVID-19 vaccine-related thrombosis: A systematic review and exploratory analysis. Front Immunol 2021;12:729251. https://doi.org/10.3389/fimmu.2021.729251.

Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol 2021;107:173-180. https://doi.org/10.1111/ejh.13665.

Calcaterra G, Bassareo PP, Barilla F, Romeo F, Mehta JL. Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown) 2022;23:71-74. https://doi.org/10.2459/jcm.0000000000001232.

Matar RH, Than CA, Nakanishi H, Daniel RS, Smayra K, Sim BL, et al. Outcomes of patients with thromboembolic events following coronavirus disease 2019 AstraZeneca vaccination: a systematic review and meta-analysis. Blood Coagul Fibrinolysis 2022;33:90-112. https://doi.org/10.1097/mbc.0000000000001113.

Cauchi M, Ball H, Ben-Shlomo Y, Robertson N. Interpretation of vaccine associated neurological adverse events: a methodological and historical review. J Neurol 2022;269:493-503. https://doi.org/10.1007/s00415-021-10747-8.

Afshar ZM, Barary M, Babazadeh A, Hosseinzadeh R, Alijanpour A, Miri SR, et al. SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review. Rev Med Virol 2022:e2327. https://doi.org/10.1002/rmv.2327.

Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022;48:8-14. https://doi.org/10.1055/s-0041-1736168.

Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci 2021;428:117607. https://doi.org/10.1016/j.jns.2021.117607.

Uzun G, Pelzl L, Singh A, Bakchoul T. Immune-mediated platelet activation in COVID-19 and vaccine-induced immune thrombotic thrombocytopenia. Front Immunol 2022;13:837629. https://doi.org/10.3389/fimmu.2022.837629.

Kashir J, Ambia AR, Shafqat A, Sajid MR, AlKattan K, Yaqinuddin A. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT). J Leukoc Biol 2022;111:725-734. https://doi.org/10.1002/jlb.5covr0621-320rr.

Simka M. Asociación de las vacunas frente a la COVID-19 basadas en vectores de adenovirus y trombosis del seno venoso cerebral: ¿guardan relación estos episodios con la formación de trampas extracelulares de neutrófilos? Vacunas 2022:4. https://doi.org/10.1016/j.vacun.2021.12.002.

Kheyrandish S, Rastgar A, Arab-Zozani M, Sarab GA. Portal vein thrombosis might develop by COVID-19 infection or vaccination: A systematic review of case-report studies. Front Med 2021;8:794599. https://doi.org/10.3389/fmed.2021.794599.

de Gregorio C, Colarusso L, Calcaterra G, Bassareo PP, Ieni A, Mazzeo AT, et al. Cerebral venous sinus thrombosis following COVID-19 vaccination: Analysis of 552 worldwide cases. Vaccines (Basel) 2022;10. https://doi.org/10.3390/vaccines10020232.

Elberry MH, Abdelgawad HAH, Hamdallah A, Abdella WS, Ahmed AS, Ghaith HS, et al. A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines. J Thromb Thrombolysis 2022:1-26. https://doi.org/10.1007/s11239-021-02626-w.

Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand 2022;145:5-9. https://doi.org/10.1111/ane.13550.

Hafeez MU, Ikram M, Shafiq Z, Sarfraz A, Sarfraz Z, Jaiswal V, et al. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): A systematic review and post hoc analysis. Clin Appl Thromb Hemost 2021;27:10760296211048815. https://doi.org/10.1177/10760296211048815.

Waqar U, Ahmed S, Gardezi S, Tahir MS, Abidin ZU, Hussain A, et al. Thrombosis with thrombocytopenia syndrome after administration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: A systematic review. Clin Appl Thromb Hemost 2021;27:10760296211068487. https://doi.org/10.1177/10760296211068487.

Favaloro EJ, Pasalic L, Lippi G. Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). Clin Chem Lab Med 2022;60:7-17. https://doi.org/10.1515/cclm-2021-1039.

Cómo citar
1.
Vizcaíno-Carruyo JC, Toro-Montoya AI. Alteraciones hematológicas como consecuencia de COVID-19 y sus vacunas. Med. Lab. [Internet]. 1 de julio de 2022 [citado 4 de diciembre de 2022];26(3):219-36. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/587
Publicado
2022-07-01
Sección
Artículos de revisión
Crossref Cited-by logo
QR Code